Our Pipeline

Our Portfolio of PIKA Technology
Product Candidates

Yisheng has three therapeutic candidates in clinical stages of development. Multiple product candidates are approaching clinical development. In addition, Yisheng has multiple programs targeting influenza, herpes zoster, Ebola and other indications at preclinical development.

Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Development Plan
PIKA
Rabies
Vaccine
Post-
exposure
prophylaxis
China Phase 1 and Multinational Phase 3
(2019)
YS-HBV-001 Hepatitis B
prevention
China
(2H19)
YS-ON-001 Advanced
solid tumors
China
(1H19)
YS-ON-002 Advanced
solid tumors
 IND
(2019)
YS-HBV-002 Chronic
hepatitis B
treatment
Multinational
Phase 1
(2020)